Ventilator-Associated Pneumonia (VAP)

COVID-19 Pandemic Heightens Need for Pulmonary Diagnostic Innovation

50% of Covid-19 deaths are co-infected with bacterial pneumonia

The world's first breath test to detect & monitor pulmonary infections.

The only test that can differentiate a virulent bacterial infection from strep pneumonia and viral lung infection.

Current standard of care vs Avisa BreathTest chart

Current standard of care chart
Avisa BreathTest chart

Value-Based, Cost Advantaged Product is a Win for Patient, Doctor, Hospital and Payer

Learn More About Clinical Applications

The Avisa BreathTestTM is well-differentiated and a paradigm shift over sputum culture

 

Sputum Culture

Sputum Culture

 Avisa BreathTest machineAvisa BreathTestTM
Sensitivity   Check mark
Specificity Check mark Urease Pathogens
Point-of-Care Testing   Check mark
Turnaround Time < 10 minutes   Check mark
Monitor Therapy   Check mark
Non-Sputum Producing Patients   Check mark

Calculated total addressable market (TAM)

Disease prevalence estimates obtained from literature

223 MILLION Total Estimated Tests Worldwide

Including US, Europe, Japan, China

Ventilator Associated Infections
17 million
Pneumonia in the Emergency Department
24 million
Cystic Fibrosis
290 thousand
C. difficile
3 million
Chronic Obstructive Pulmonary
178 million
 
TAM By Indication

Indications for use tested in interviews with physicians, respiratory therapists, insurance plan chief medical officers and Avisa medical advisory board.

Download Full Market Size Research Overview

Interested in learning more?

Contact us today to speak with an Avisa Expert!

Contact Us

Subscribe to our newsletter